// App-Quantinova.ai

: Single-Agent Ibrutinib Versus Chlorambucil-Obinutuzumab As First-Line Treatment in Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (CLL/SLL): Results of a Cross-Trial Comparison

Researchers

Presenter

  • Alessandra Tedeschi

Principal Investigators

  • Fatih Demirkan

  • Tadeusz Robak

  • Carol Moreno

  • Paul Barr

  • Bertrand Anz

  • David Simpson

  • Gianluca Gaidano

  • Osnat Bairey

  • Don Stevens

  • Devinder Gill

  • Ian W. Flinn

  • Thomas J. Kipps

  • Jan A. Burger

  • Jennifer Lin

  • Thomas Webb

  • Viktor Fedorov

  • Lori Styles

  • John G. Gribben

Medical Centers

  • Grande Ospedale Metropolitano Niguarda, Milan, Italy

  • Paracelsus Medical University, Salzburg Cancer Research Institute, and Cancer Cluster Salzburg, Salzburg, Austria

  • Dokuz Eylul University, Izmir, Turkey

  • Medical University of Lodz and Copernicus Memorial Hospital, Lodz, Poland

  • Hospital del Mar, Autonomous University of Barcelona, Barcelona, Spain

  • University of Rochester Medcal Center, Rochester, NY

  • Tennessee Oncology, Chattanooga, TN

  • North Shore Hosp, Auckland, New Zealand

  • Department of Health Sciences Amedeo Avogadro University of Eastern Piedmont Novara Italy

  • Rheumatology Unit, Rabin Medical Center, Beilinson Hospital and Sackler Faculty of Medicine, Tel Aviv University, Petach Tikva, Israel

  • Norton Cancer Institute, Louisville, KY

  • Princess Alexandra Hospital, Brisbane, Australia

  • Sarah Cannon Research Institute/Tennessee Oncology, PLLC, Nashville, TN

  • University of California, San Diego, Moores Cancer Center, La Jolla, CA

  • The University of Texas MD Anderson Cancer Canter, Houston, TX

  • Pharmcyclics LLC, an AbbVie Company, Sunnyvale, CA

  • Janssen Cilag, High Wycombe, United Kingdom

  • Barts Cancer Institute, Queen Mary University of London, London, United Kingdom

Locations

  • Italy

  • Austria

  • Turkey

  • Poland

  • Spain

  • United States

  • New Zealand

  • Israel

  • Australia

  • United Kingdom

Companies

  • Pharmacyclics LLC

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Chronic Lymphocytic Leukemia

  • Lymphomas

Biomarkers

  • Immunoglobulin heavy-chain variable region gene

  • Tumor protein p53

Drug/Treatment

  • Obinutuzumab

  • Obinutuzumab Intravenous

  • chlorambucil

  • Ibrutinib

  • TP53

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved